Sorry, the page you are looking for has moved to a new URL. Please click here to go to the new page.

We wanted to come up with a reasonable minimum estimate of how much the tax will bring in, using as close to real-world numbers as we could find, and assess what its impact might be on companies’ bottom lines.

Because the tax is a 2.3% levy on U.S. sales only, we pored over the annual reports and filings of 49 companies selected from our Big 100 book of the world’s largest med-tech players to isolate domestic revenues for fiscal 2011.

There are some obvious problems with this method. For most of the companies on our list, which are pure-play device makers, this was relatively easy. But for the firms with business lines outside of the medical device space, this was a challenge.

Johnson & Johnson (NYSE:JNJ), for example, only breaks out U.S. sales for its medical device and diagnostics segment, making it well nigh impossible to parse U.S. sales for devices only. Other companies, such as Zimmer (NYSE:ZMH) or Fresenius (NYSE:FMS), report geographic segments for the Americas or for North America. Still others, like Symmetry Medical (NYSE:SMA), report U.S. sales as a percentage of total sales.

And we only looked at 49 of the Big 100 companies. There are hundreds of medical device companies selling into the U.S. market, meaning that the actual amount generated by the tax is likely to be a lot larger than our $2 billion, back-of-the-envelope calculation.

Footnotes
^1: Medical device & diagnostics segment only, 2011
² U.S. net sales, FY2011 (ended 4/29/2011)
³ U.S. sales, Healthcare segment – Americas, FY2011 (ended 9/30/2011)
⁴ Medical products segment, U.S. sales, 2011
⁵ Healthcare segment’s North American sales, 2011
⁶ U.S. sales, 2011
⁷ 54% of 2011 net sales of $7.622B
⁸ Medical device segment’s U.S. sales, FY2011 (ended 9/30/11)
⁹ U.S. sales, FY2011 (ended 6/30/2011)
¹⁰ 80% of U.S. sales, 2011 of $3.4B
¹¹ U.S. sales, 2011
¹² U.S. sales for vascular, diabetes and medical optics segments, 2011
¹³ U.S. sales, 2011 for dental, life science segments
¹⁴ Americas sales 2011
¹⁵ U.S. sales, 2011
¹⁶ U.S. sales, 2011
¹⁷ U.S. sales, 2011
¹⁸ U.S. sales,FY 2011 (ended 9/24/2011)
¹⁹ Fresenius KABI’s North American sales, Fresenius Medical Care’s North American dialysis product sales, FY2011
²⁰ U.S. sales, FY2011 (ended 9/30/2011)
²¹ Medication management segment sales (24% of total 2011 sales of $4057.1B), 2011
²² U.S. sales, 2011
²³ Patient-care services and therapeutic solutions segment sales = 89.1% of total sales (no significant OUS sales), 2011
²⁴ U.S. sales, 2011
²⁵ U.S. sales, FY2011 (ended 10/31/11)
²⁶ U.S. sales, 2011 (TFX estimates $15M in 2013)
²⁷ U.S. sales, FY2011 (ended 6/30/11)
²⁸ U.S. sales, 2011
²⁹ U.S. sales, 2011
³⁰ U.S. sales = 62%, U.S. medical device sales = $915.1M, 2011
³¹ U.S. sales, 2011
³² U.S. sales = 75% of total sales of $579.0M, 2011
³³ U.S. sales, 2011
³⁴ U.S. sales, 2011
³⁵ U.S. sales, FY2011 (ended 10/2/11) (ZOLL estimates $10M in 2013)
³⁶ U.S. sales, 2011
³⁷ U.S. sales, FY2011 (ended 4/2/2011)
³⁸ U.S. sales, 2011
³⁹ U.S. sales, 2011
⁴⁰ U.S. sales, FY2011 (ended 7/31/2012)
⁴¹ U.S. sales, 2011 = 72.8% of total sales of $359M
⁴² U.S. sales, FY2011 (ended 9/30/11)
⁴³ U.S. sales, 2011
⁴⁴ U.S. sales, 2011
⁴⁵ U.S. sales, 2011
⁴⁶ U.S. sales = 45% of medical device sales of $489.1M, FY2011 (ended 12/30/2011)
⁴⁷ U.S. sales, 2011
⁴⁸ U.S. sales, 2011
⁴⁹ U.S. medical sales = 89% of $161.7M, FY2011 (ended 7/31/11)